Suppression of Coronavirus Replication by Cyclophilin Inhibitors

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2013 May 24

PMID 23698397

Citations 107

Authors

Yoshikazu Tanaka

Yuka Sato

Takashi Sasaki

Affiliations

Soon will be listed here.

Abstract

Coronaviruses infect a variety of mammalian and avian species and cause serious diseases in humans, cats, mice, and birds in the form of severe acute respiratory syndrome (SARS), feline infectious peritonitis (FIP), mouse hepatitis, and avian infectious bronchitis, respectively. No effective vaccine or treatment has been developed for SARS-coronavirus or FIP virus, both of which cause lethal diseases. It has been reported that a cyclophilin inhibitor, cyclosporin A (CsA), could inhibit the replication of coronaviruses. CsA is a well-known immunosuppressive drug that binds to cellular cyclophilins to inhibit calcineurin, a calcium-calmodulin-activated serine/threonine-specific phosphatase. The inhibition of calcineurin blocks the translocation of nuclear factor of activated T cells from the cytosol into the nucleus, thus preventing the transcription of genes encoding cytokines such as interleukin-2. Cyclophilins are peptidyl-prolyl isomerases with physiological functions that have been described for many years to include chaperone and foldase activities. Also, many viruses require cyclophilins for replication; these include human immunodeficiency virus, vesicular stomatitis virus, and hepatitis C virus. However, the molecular mechanisms leading to the suppression of viral replication differ for different viruses. This review describes the suppressive effects of CsA on coronavirus replication.

Citing Articles

Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial.

Llanos Jimenez L, Alvarez-Alvarez B, Fonseca Aizpuru E, Peces-Barba G, Pindao Quesada G, Rodriguez Nieto M J Clin Med. 2024; 13(17).

PMID: 39274454 PMC: 11396137. DOI: 10.3390/jcm13175242.

Cyclophilin inhibition as a strategy for the treatment of human disease.

Stauffer W, Goodman A, Gallay P Front Pharmacol. 2024; 15:1417945.

PMID: 39045055 PMC: 11264201. DOI: 10.3389/fphar.2024.1417945.

A Retrospective and Comparative Analysis of Clinical Outcomes of Kidney Transplant Recipients During First and Second COVID-19 Waves in North-West India.

Bhagat C, Gurnani N, Godara S, Mathur R, Goel A, Meshram H Cureus. 2024; 16(1):e51693.

PMID: 38313994 PMC: 10838483. DOI: 10.7759/cureus.51693.

Potential Alternative Receptors for SARS-CoV-2-Induced Kidney Damage: TLR-4, KIM-1/TIM-1, and CD147.

Habeichi N, Amin G, Lakkis B, Kataya R, Mericskay M, Booz G Front Biosci (Landmark Ed). 2024; 29(1):8.

PMID: 38287815 PMC: 10924798. DOI: 10.31083/j.fbl2901008.

Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines.

Tasker S, Addie D, Egberink H, Hofmann-Lehmann R, Hosie M, Truyen U Viruses. 2023; 15(9).

PMID: 37766254 PMC: 10535984. DOI: 10.3390/v15091847.

References

Chen Z, Mi L, Xu J, Yu J, Wang X, Jiang J . Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus. J Infect Dis. 2005; 191(5):755-60. PMC: 7110046. DOI: 10.1086/427811. View

Brockway S, Denison M . Mutagenesis of the murine hepatitis virus nsp1-coding region identifies residues important for protein processing, viral RNA synthesis, and viral replication. Virology. 2005; 340(2):209-23. PMC: 7111834. DOI: 10.1016/j.virol.2005.06.035. View

Leung A, Varanyuwatana P, Halestrap A . The mitochondrial phosphate carrier interacts with cyclophilin D and may play a key role in the permeability transition. J Biol Chem. 2008; 283(39):26312-23. PMC: 3258905. DOI: 10.1074/jbc.M805235200. View

Gaither L, Borawski J, Anderson L, Balabanis K, Devay P, Joberty G . Multiple cyclophilins involved in different cellular pathways mediate HCV replication. Virology. 2009; 397(1):43-55. DOI: 10.1016/j.virol.2009.10.043. View

Zhou D, Mei Q, Li J, He H . Cyclophilin A and viral infections. Biochem Biophys Res Commun. 2012; 424(4):647-50. PMC: 7092870. DOI: 10.1016/j.bbrc.2012.07.024. View

Takeuchi H . Contribution of Cyclophilin A to determination of simian immunodeficiency virus tropism: a progress update. Vaccine. 2010; 28 Suppl 2:B51-4. DOI: 10.1016/j.vaccine.2009.10.020. View

Zust R, Cervantes-Barragan L, Kuri T, Blakqori G, Weber F, Ludewig B . Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines. PLoS Pathog. 2007; 3(8):e109. PMC: 1941747. DOI: 10.1371/journal.ppat.0030109. View

de Wilde A, Zevenhoven-Dobbe J, van der Meer Y, Thiel V, Narayanan K, Makino S . Cyclosporin A inhibits the replication of diverse coronaviruses. J Gen Virol. 2011; 92(Pt 11):2542-2548. PMC: 3352363. DOI: 10.1099/vir.0.034983-0. View

Perlman S, Netland J . Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol. 2009; 7(6):439-50. PMC: 2830095. DOI: 10.1038/nrmicro2147. View

10.

Bose S, Mathur M, Bates P, Joshi N, Banerjee A . Requirement for cyclophilin A for the replication of vesicular stomatitis virus New Jersey serotype. J Gen Virol. 2003; 84(Pt 7):1687-1699. DOI: 10.1099/vir.0.19074-0. View

11.

Wathelet M, Orr M, Frieman M, Baric R . Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol. 2007; 81(21):11620-33. PMC: 2168762. DOI: 10.1128/JVI.00702-07. View

12.

Anderson S, Gallinger S, Roder J, Frey J, Young H, Ortaldo J . A cyclophilin-related protein involved in the function of natural killer cells. Proc Natl Acad Sci U S A. 1993; 90(2):542-6. PMC: 45699. DOI: 10.1073/pnas.90.2.542. View

13.

Teigelkamp S, Achsel T, Mundt C, Gothel S, Cronshagen U, Lane W . The 20kD protein of human [U4/U6.U5] tri-snRNPs is a novel cyclophilin that forms a complex with the U4/U6-specific 60kD and 90kD proteins. RNA. 1998; 4(2):127-41. PMC: 1369602. View

14.

Billich A, Hammerschmid F, Peichl P, Wenger R, Zenke G, Quesniaux V . Mode of action of SDZ NIM 811, a nonimmunosuppressive cyclosporin A analog with activity against human immunodeficiency virus (HIV) type 1: interference with HIV protein-cyclophilin A interactions. J Virol. 1995; 69(4):2451-61. PMC: 188920. DOI: 10.1128/JVI.69.4.2451-2461.1995. View

15.

Yurchenko V, Zybarth G, OConnor M, Dai W, Franchin G, Hao T . Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem. 2002; 277(25):22959-65. DOI: 10.1074/jbc.M201593200. View

16.

Satoh K, Shimokawa H, Berk B . Cyclophilin A: promising new target in cardiovascular therapy. Circ J. 2010; 74(11):2249-56. PMC: 3052698. DOI: 10.1253/circj.cj-10-0904. View

17.

Nagy P, Wang R, Pogany J, Hafren A, Makinen K . Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. Virology. 2011; 411(2):374-82. DOI: 10.1016/j.virol.2010.12.061. View

18.

Tanaka Y, Sato Y, Osawa S, Inoue M, Tanaka S, Sasaki T . Suppression of feline coronavirus replication in vitro by cyclosporin A. Vet Res. 2012; 43:41. PMC: 3403912. DOI: 10.1186/1297-9716-43-41. View

19.

Provencher V, Coccaro E, Lacasse J, Schang L . Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance. Curr Pharm Des. 2004; 10(32):4081-101. DOI: 10.2174/1381612043382422. View

20.

Watashi K, Ishii N, Hijikata M, Inoue D, Murata T, Miyanari Y . Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005; 19(1):111-22. DOI: 10.1016/j.molcel.2005.05.014. View